Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
The purpose of this study is to assess the safety and effectiveness of the investigational immunotherapy LN-145 in patients with non-small cell lung cancer (NSCLC) that has metastasized despite prior treatment. LN-145 is called "autologous tumor infiltrating lymphocytes" (TIL) therapy. It activates white blood cells to attack the tumor.
Researchers are comparing different sequences of therapy for people with newly diagnosed multiple myeloma. All participants will get cilta-cel CAR T-cell therapy, a form of immunotherapy made from your own white blood cells.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
ARV-393 targets and breaks down a protein called BCL6. This protein is found in cancer cells and plays a role in their growth and survival. By breaking down BCL6, ARV-393 may help slow or stop the growth of your cancer. It is taken orally (by mouth).
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are assessing maintenance therapy with olaparib given for 1 or 2 years, with or without bevacizumab, to treat ovarian cancer. The people in this study have stage 3 or 4 ovarian cancer with certain genetic mutations (changes).
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
